Andere talen Navidea Biopharmaceuticals, Inc.

Aandelen

NAVB

US63937X2027

Vertraagde tijd OTC Markets Andere beurzen 21:16:59 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,035 ^USD	0,00%		-12,50%	-36,59%

2023	Navidea Biopharmaceuticals, Inc. rapporteert resultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2023	CI
2023	Sectorupdate: Gezondheidszorg	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release	04/12
Navidea Biopharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding	27/11
Navidea: Q3 Earnings Snapshot	15/11
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Navidea Biopharmaceuticals, Inc.(OTCPK:NAVB) dropped from S&P TMI Index	11-10-23
Sector Update: Health Care	06-10-23
Top Midday Decliners	06-10-23
Navidea Biopharmaceuticals Says NYSE American Panel Upheld Delisting Decision	06-10-23
Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock	06-10-23
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11-08-23
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel	10-08-23
Navidea Biopharmaceuticals, Inc. Announces Resignation of Malcolm G. Witter as Director, Member of the Audit Committee and Compensation, Nominating and Governance Committee of the Board	08-08-23
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination	31-07-23
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities	31-07-23
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination	29-07-23
Navidea Biopharmaceuticals, Inc. Announces Executive Changes	28-07-23
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer	27-07-23
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer	27-07-23
Navidea Biopharmaceuticals, Inc. Announces Board Changes	13-07-23
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down	13-07-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Navidea Biopharmaceuticals, Inc.

Aandelen

NAVB

US63937X2027

Andere talen

Filters